Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

Neurology

Volumn 54, Issue 5, 2000, Pages 1099-1102

  Otto, Markus ^a   Esselmann, H ^b   Schulz Schaeffer, W ^b   Neumann, M ^b   Schroter A ^b   Ratzka, P ^b   Cepek, L ^b   Zerr, I ^b   Steinacker, P ^b   Windl, O ^b   Kornhuber, J ^b   Kretzschmar, H A ^b   Poser, S ^b   Wiltfang, J ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b NONE

Author keywords

AD; Amyloid beta; APOE allele; A 1 42; Creutzfeldt Jakob disease; Laboratory diagnosis; Protein 14 33

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; PRION PROTEIN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; CEREBROSPINAL FLUID; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID BETA-PROTEIN; CREUTZFELDT-JAKOB SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED;

EID: 0034646142     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.5.1099     Document Type: Article

References (41)

1. Chesebro B. BSE and prions: uncertainties about the agent. Science 1998;279:42-43.
2. Safar J. The folding intermediate concept of prion protein formation and conformational links to infectivity. Curr Top Microbiol Immunol 1996;207:77-93.
3. Prusiner SB. Prion diseases and the BSE crisis. Science 1997; 278:245-251.
4. Eigen M. Prionics or the kinetic basis of prion diseases. Biophys Chem 1996;63:A1-18.
5. Brown P, Gibbs CJJ, Rodgers-Johnson P, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994;35:513-529.
6. Masters CL, Harris JO, Gajdusek DC, et al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177-188.
7. Will RG. Epidemiology of Creutzfeldt-Jakob disease. Br Med Bull 1993;49:960-970.
8. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924-930.
9. Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 1998;43:32-40.
10. Otto M, Stein H, Szudra A, et al. S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 1997;244:566-570.
11. Zerr I, Bodemer M, Räcker S, et al. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 1995;345:1609-1610.
12. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210-212.
13. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community-based follow-up study. J Neurol Neurosurg Psychiatry 1998;64:298-305.
14. Vigo Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995;45:788-793.
15. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett 1996;212:209-211.
16. Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991;251:675-678.
17. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120: 885-890.
18. Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992;258:126-129.
19. Masters CL, Multhaup G, Simms G, et al. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 1985;4:2757-2763.
20. Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 1995;270:7013-7016.
21. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
22. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26.
23. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673-680.
24. Galasko D; Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945.
25. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-1562.
26. Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996;53:913-920.
27. Parchi P, Castellani R, Capellari S, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996;39:767-778.
28. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46:224-233.
29. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
30. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association, 1994.
31. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
32. Hyman BT, Trojanowski JQ. Editorial on Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. J Neuropathol Exp Neurol 1997;56:1095-1097.
33. Hesse C, Minthon L, Wallin A, et al. Tau protein and β-amyloid(1-42) in cerebrospinal fluid from Alzheimer's disease patients and controls. Neurobiol Aging 1998;19:S163. Abstract.
34. Miyazono M, Kitamoto T, Iwaki T, Tateishi J. Colocalization of prion protein and beta protein in the same amyloid plaques in patients with Gerstmann-Straussler syndrome. Acta Neuropathol (Berl) 1992;83:333-339.
35. Ghersi-Egea JF, Gorevic PD, Ghiso J, et al. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 1996;67:880-883.
36. Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 1998;4:832-834.
37. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
38. Narita M, Holtzman DM, Schwartz AL, Bu G. Alpha 2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem 1997;69:1904-1911.
39. Kuo YM, Emmerling MR, Lampert HC, et al. High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 1999;257: 787-791.
40. Chapman J, Cervenakova L, Petersen RB, et al. APOE in non-Alzheimer amyloidoses: transmissible spongiform encephalopathies. Neurology 1998;51:548-553.
41. Zerr I, Helmhold M, Poser S, Armstrong VW, Weber T. Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease. Arch Neurol 1996;53:1233-1238.